Eleonora Nencini

Eleonora graduated in Biotechnology at the University of Florence in April 2020 with a thesis on the use of synthetic peptides for the evaluation of the anti-drug antibody response in patients affected by juvenile idiopathic arthritis and treated with the therapeutic monoclonal antibody Adalimumab.

In October 2022 she obtained her Master’s Degree in Sustainable Industrial Pharmaceutical Biotechnology at the University of Siena, carrying out the experimental thesis work within the MAD-Lab of the Fondazione Toscana Life Sciences (TLS), under the supervision of Dr. Samuele Stazzoni. Her thesis project is based on the synthesis and characterization of mRNA-encoded monoclonal antibodies, previously identified and isolated by the MAD-Lab team, directed against Klebsiella pneumoniae and SARS-CoV-2.

Since January 2023, Eleonora has a fellowship at the University of Siena and is part of the laboratory of Dr. Rino Rappuoli at the Fondazione Toscana Life Sciences (TLS), where she works in “Wellcome Leap – RNA Readiness + Response (R3) Program” project.

Research Group: